Company · CIK 1750149
Inhibikase Therapeutics, Inc.
| CIK | 1750149 (SEC EDGAR) |
|---|---|
| Industry (SIC) | 2836 — Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
| Business address | DE |
| Listed | IKT (Nasdaq) |
| First annual or quarterly report | 2021-03-31 |
Offerings
9 registrations| Registration | Label and status | First filed | Last event | Filings |
|---|---|---|---|---|
| 333-288213 | 2025-06-20 | 2025-12-19 | 5 | |
| 333-284222 | 2025-01-10 | 2025-01-16 | 2 | |
| 333-283307 | 2024-11-18 | 2024-12-05 | 2 | |
| 333-280317 | 2024-06-18 | 2024-06-26 | 2 | |
| 333-262551 | 2022-02-07 | 2024-05-22 | 7 | |
| 333-278844 | 2024-04-19 | 2024-05-15 | 6 | |
| 333-269521 | 2023-02-02 | 2023-04-04 | 3 | |
| 333-257032 | 2021-06-11 | 2021-06-17 | 3 | |
| 333-240036 | 2020-07-23 | 2020-12-28 | 8 |
Filings
40| Filed | Filing | Registration | Accession |
|---|---|---|---|
| 2025-12-19 | 424B5Shelf takedown | 333-288213 | 0001193125-25-326883 |
| 2025-11-21 | 424B5Shelf takedown | 333-288213 | 0001193125-25-291433 |
| 2025-11-20 | 424B5Shelf takedown | 333-288213 | 0001193125-25-289894 |
| 2025-06-27 | EFFECTDeclared effective | 333-288213 | 9999999995-25-002070 |
| 2025-06-20 | S-3Shelf registered | 333-288213 | 0001193125-25-143738 |
| 2025-01-16 | EFFECTDeclared effective | 333-284222 | 9999999995-25-000136 |
| 2025-01-10 | S-3Shelf registered | 333-284222 | 0001193125-25-004494 |
| 2024-12-05 | EFFECTDeclared effective | 333-283307 | 9999999995-24-003676 |
| 2024-11-18 | S-3Shelf registered | 333-283307 | 0001193125-24-260973 |
| 2024-06-26 | EFFECTDeclared effective | 333-280317 | 9999999995-24-001978 |
| 2024-06-18 | S-1Registration filed | 333-280317 | 0001193125-24-163529 |
| 2024-05-22 | 424B5Shelf takedown | 333-262551 | 0001193125-24-144499 |
| 2024-05-20 | 424B5Shelf takedown | 333-262551 | 0001193125-24-142213 |
| 2024-05-15 | RWWithdrawn | 333-278844 | 0001193125-24-138902 |
| 2024-05-09 | S-1/AAmendment | 333-278844 | 0001193125-24-135161 |
| 2024-05-09 | S-1/AAmendment | 333-278844 | 0001193125-24-134515 |
| 2024-04-29 | S-1/AAmendment | 333-278844 | 0001193125-24-122506 |
| 2024-04-25 | S-1/AAmendment | 333-278844 | 0001193125-24-113987 |
| 2024-04-19 | S-1Registration filed | 333-278844 | 0001193125-24-103050 |
| 2024-02-01 | 424B5Shelf takedown | 333-262551 | 0001193125-24-021918 |
| 2023-04-04 | EFFECTDeclared effective | 333-269521 | 9999999995-23-000817 |
| 2023-02-07 | EFFECTDeclared effective | 333-269521 | 9999999995-23-000304 |
| 2023-02-02 | S-1Registration filed | 333-269521 | 0001193125-23-021876 |
| 2023-01-27 | 424B5Shelf takedown | 333-262551 | 0001193125-23-016884 |
| 2022-05-17 | 424B5Shelf takedown | 333-262551 | 0001193125-22-152245 |
| 2022-02-11 | EFFECTDeclared effective | 333-262551 | 9999999995-22-000439 |
| 2022-02-07 | S-3Shelf registered | 333-262551 | 0001193125-22-028552 |
| 2021-06-17 | 424B4Final prospectus | 333-257032 | 0001193125-21-193231 |
| 2021-06-15 | EFFECTDeclared effective | 333-257032 | 9999999995-21-002358 |
| 2021-06-11 | S-1Registration filed | 333-257032 | 0001193125-21-188903 |
| 2021-06-02 | DRSDraft made public | 377-04957 | 0000950123-21-007495 |
| 2020-12-28 | 424B4Final prospectus | 333-240036 | 0001104659-20-139346 |
| 2020-12-22 | EFFECTDeclared effective | 333-240036 | 9999999995-20-003606 |
| 2020-12-04 | S-1/AAmendment | 333-240036 | 0001104659-20-132319 |
| 2020-11-03 | S-1/AAmendment | 333-240036 | 0001104659-20-120661 |
| 2020-10-16 | S-1/AAmendment | 333-240036 | 0001104659-20-115393 |
| 2020-09-30 | S-1/AAmendment | 333-240036 | 0001104659-20-110071 |
| 2020-09-15 | S-1/AAmendment | 333-240036 | 0001104659-20-105312 |
| 2020-07-23 | S-1Registration filed | 333-240036 | 0001104659-20-085909 |
| 2018-08-31 | DRSDraft made public | 377-02245 | 0001144204-18-047405 |